<DOC>
	<DOC>NCT01886599</DOC>
	<brief_summary>The purpose of the study is to determine how Asunaprevir is handled by the body of subjects with kidney disease compared with subjects with normal kidney function</brief_summary>
	<brief_title>Study of the Pharmacokinetics and Safety of Asunaprevir in Patients With Kidney Disease</brief_title>
	<detailed_description>Primary Purpose: Other: The purpose of the study is to determine how Asunaprevir is handled by the body of subjects with kidney disease compared with subjects with normal kidney function</detailed_description>
	<mesh_term>Hepatitis C</mesh_term>
	<criteria>Group A: Subjects with normal renal function Group B: Patients with end stage renal disease Group C: Patients with mild renal impairment Group D: Patients with moderate renal impairment Group E: Patients with severe renal impairment History of uncontrolled or unstable cardiovascular, respiratory, hepatic, gastrointestinal, endocrine, hematopoietic, psychiatric and/or neurological disease Hepatitis B or C Human Immunodeficiency Virus (HIV) Recent gastrointestinal disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>